(Q45722797)

15 December 2017

Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita (English)

1 reference

15 December 2017

epidermolysis bullosa

1 reference

7

1 reference

15 December 2017

8

Detlef Zillikens

1 reference

15 December 2017

Misa Hirose

1

1 reference

15 December 2017

Benjamin Tiburzy

2

1 reference

15 December 2017

Norito Ishii

3

1 reference

15 December 2017

Elena Pipi

4

1 reference

15 December 2017

Sabina Wende

5

1 reference

15 December 2017

Ellen Rentz

6

1 reference

15 December 2017

Rudolf A Manz

9

1 reference

15 December 2017

Ralf J Ludwig

10

1 reference

15 December 2017

Michael Kasperkiewicz

11

1 reference

15 December 2017

language of work or name

English

0 references

publication date

20 October 2014

1 reference

Journal of Investigative Dermatology

15 December 2017

1 reference

15 December 2017

135

1 reference

15 December 2017

3

1 reference

15 December 2017

768-775

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2014.453

15 December 2017

0 references

cites work

Indications and safety of intravenous and subcutaneous immunoglobulin therapy

1 reference

12 December 2020

The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita

1 reference

12 December 2020

Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice

1 reference

12 December 2020

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

1 reference

12 December 2020

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

1 reference

12 December 2020

Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen

1 reference

12 December 2020

Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris

1 reference

12 December 2020

B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita

1 reference

12 December 2020

Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation

1 reference

12 December 2020

Current treatment of autoimmune blistering diseases

1 reference

12 December 2020

Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita

1 reference

12 December 2020

Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen

1 reference

12 December 2020

Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker

1 reference

12 December 2020

High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases

1 reference

12 December 2020

Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

1 reference

12 December 2020

Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita.

1 reference

12 December 2020

Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus

1 reference

12 December 2020

Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice

1 reference

12 December 2020

Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris

1 reference

12 December 2020

Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita

1 reference

12 December 2020

T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita

1 reference

12 December 2020

Identification of the Skin Basement-Membrane Autoantigen in Epidermolysis Bullosa Acquisita

1 reference

12 December 2020

Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets

1 reference

12 December 2020

Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid

1 reference

12 December 2020

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

1 reference

12 December 2020

NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage

1 reference

12 December 2020

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

1 reference

12 December 2020

Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury

1 reference

12 December 2020

Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen

1 reference

12 December 2020

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

1 reference

12 December 2020

Identifiers

DOI

10.1038/JID.2014.453

1 reference

Dimensions Publication ID

15 December 2017

0 references

1 reference